First Female Professional CEO in Samsung Group’s history

Samsung Bioepis Appoints Kim Kyung-ah as New CEO After 13 Years

Presented at the Asia-Pacific Digestive Disease Week

Daewoong "Ursa Shows Liver Function Improvement in Phase 4 Trial"

Celltrion Secures First Approval for Prolia Biosimilar in Korea

Signs 930.4 Billion KRW Contract with European Pharmaceutical Company

Samsung Biologics Breaks 5 Trillion KRW in Annual Orders for the First Time

Accelerated Global Expansion Expected

FDA Approved VUNO’s AI Chest X-ray Diagnostic Device

First Major Pharma Collaboration... Expansion Beyond Lung Cancer Expected

Lunit Partners with AstraZeneca to Develop ‘AI Pathology Solution’

"Switching to Direct Sales Model"

Celltrion Acquires Swiss Pharmaceutical Distributor, iQone Healthcare Switzerland

Park Soon-Jae, CEO of Alteogen: “Creating a ‘Golden Egg’ Platform”

Global Pharma Companies Lining Up at Alteogen's Door – Why?

The event comprised lecture and live demonstration for facial filler injection

Hugel Successfully Concludes HA Filler workshop for French medical experts

echnology to Develop Subcutaneous Injection for ADC Cancer Drug 'Enhertu'

Alteogen Signs USD 280 Million Licensing Agreement with Daiichi Sankyo

Operating profit up 54.5% to 53.4 billion KRW

Hugel Sees Record Q3 Revenue and Profit with Botulax Growth

Acquires 31.5% Stake, Secures Production Base for Hyaluronidase Raw Materials

Huons Acquires PanGen... “Expanding CDMO Services for Biopharmaceuticals”

"Lower Incidence of Brain Hemorrhage and Edema in East Asians"

Korean Dementia Association: “Leqembi's Side Effects Are Not Significant”

Exceeds Last Year's Performance in Just Three Quarters

Samsung Bioepis Projected to Reach 1.4 Trillion KRW in Sales

Success from Co-Promotion of K-CAB and Legacy Brands Acquisition

Boryung Nearing 1 Trillion KRW in Annual Sales for the First Time

License revenue 98.1 billion KRW, with sales up 24.8% to 585.2 billion KRW

Yuhan Corporation's Q3 Operating Profit Surges 690%

Expanding Client Base Drives Optimism, with Targets Raised to Around 1.3 Million KRW

Strong Performance Drives Samsung Biologics’ Price Target Upward

First Korean-Developed Flu Vaccine to Gain Market Authorization in Indonesia

SK bioscience's Influenza Vaccine ‘SkyCellflu’ Approved in Indonesia

First time surpassing 4 trillion KRW in cumulative orders since founding

Samsung Biologics Secures Record 1.7 Trillion KRW Contract

Quarterly Operating Losses Persist Since Last Year, and R&D Pipeline Shrinks

Bukwang's Performance Declines Over 2.5 Years Under OCI: Will Q3 Bring a Turnaround?